Skip to main content

Targeting assembly of infectious HIV particles

Objective

AIDS remains one of the major life threatening infectious diseases in the world today. A constant supply of novel antiretrovirals (ARVs) is needed to respond to the limitations of current drugs. By the end of 2007, the therapeutic arsenal against HIV is expected to comprise ARVs blocking all major steps of HIV replication, except for particle assembly and budding. Members of HIV-ACE were instrumental in recent breakthroughs concerning virus assembly and Envelope incorporation into virions. On the basis of novel and fully validated targets, the objectives of HIV-ACE are: i) Assay development, drug screening and pre-clinical development of small molecule inhibitors of Capsid assembly and Env incorporation, up to the stage of Early Drug Candidates with acceptable toxicity profile determined by ADME/Tox studies, activity against multi drug-resistant viral strains and primary non-B isolates, antiviral activity in primary T cells and macrophages (WP1); ii) Elucidation of 3D structures of these validated targets and rational drug design guided by molecular modelling and docking of inhibitors (WP2); iii) validation and exploitation of the HIV-susceptible transgenic rat model to allow preclinical in vivo-evaluation of novel drug candidates from HIV-ACE and to provide the European pharmaceutical industry with an efficient in vivo-platform for predictive testing of any kind of anti-HIV drug (WP3); iv) Elucidation of the mechanisms responsible for activity of the validated inhibitors, and discovery/validation of novel targets in the budding pathway of HIV-1 (WP4). HIV-ACE is composed of 8 teams from 5 European countries, including a Biopharma SME, led by prominent world-class scientists in Virology, Cell Biology, Immunology, Organic and Medicinal Chemistry, working in highly regarded research organisations. To efficiently achieve the ambitious goals of HIV-ACE, strong management led by a very experienced organisation has been included in a separate coordination-management WP5.

Call for proposal

FP7-HEALTH-2007-A
See other projects for this call

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Address
Rue De Tolbiac 101
75654 Paris
France
Activity type
Research Organisations
EU contribution
€ 360 000
Administrative Contact
Lyddie Laaland (Ms.)

Participants (7)

UNIVERSITATSKLINIKUM HEIDELBERG
Germany
EU contribution
€ 757 000
Address
Im Neuenheimer Feld 672
69120 Heidelberg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Thorsten Brietz (Mr.)
MEDICAL RESEARCH COUNCIL
United Kingdom
EU contribution
€ 310 000
Address
North Star Avenue Polaris House
SN2 1FL Swindon
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Claire Hebblethwaite (Ms.)
INSTITUT PASTEUR
France
EU contribution
€ 337 000
Address
Rue Du Docteur Roux 25-28
75724 Paris Cedex 15
Activity type
Research Organisations
Administrative Contact
Nadia Khelef (Dr.)
USTAV ORGANICKE CHEMIE A BIOCHEMIE, AV CR, V.V.I.
Czechia
EU contribution
€ 180 000
Address
Flemingovo Nam. 542/2
16610 Praha 6
Activity type
Research Organisations
Administrative Contact
Bozena Petschova (Dr.)
INSERM TRANSFERT SA
France
EU contribution
€ 165 000
Address
Rue Watt 7
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Louis Jammayrac (Mr.)
UNIVERSITE DE GENEVE
Switzerland
EU contribution
€ 325 000
Address
Rue Du General Dufour 24
1211 Geneve
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Nicole Mouthon (Ms.)
LABORATOIRE BIODIM
France
EU contribution
€ 566 000
Address
Rue De Grenelle 84
75007 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Séverine Burdel (Ms.)